Meanwhile, the European Union - funded SYMPATH Project has received nearly $ 6 million from the Seventh Framework Program to test AFFiRiS» AS - targeting vaccines in patients suffering
with synucleinopathies.
A new article published by JAMA Neurology compares survival rates among patients
with synucleinopathies, including Parkinson disease, dementia with Lewy bodies, Parkinson disease dementia and multiple system atrophy with parkinsonism, with individuals in the general population.
Overall, patients
with synucleinopathies died about two years earlier than participants without in the comparison group.
Of the 461 patients
with synucleinopathies, 316 (68.6 percent) died during follow - up, while among the 452 participants used for comparison, 220 (48.7 percent) died during follow - up.
The population - based study by Rodolfo Savica, M.D., Ph.D., and coauthors of the Mayo Clinic, Rochester Minn., included all the residents of Minnesota's Olmsted County and identified 461 patients
with synucleinopathies and 452 patients without for comparison.
Not exact matches
Although several large studies have shown that α - synuclein levels are lower in the CSF of PD patients and those
with related
synucleinopathies compared to controls, its role in cognitive decline and dementia had been unexplored.
AFF 1: Preclinical Efficacy Data AFF 1 was then tested for preclinical efficacy in two models of human
synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model
with closer neuropathological and metabolic resemblance to LBD than PD.